Hsueh Chi-Yao, Yuan Xiaohui, Huang Huiying, Shen Yujie, Huang Qiang, Dong Weida, Li Danhui, Lau Hui-Ching, Mao Xinhui, Liang Simin, Tao Lei, Zhang Ming, Sun Ji, Gong Hongli
ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Department of Otorhinolaryngology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
NPJ Biofilms Microbiomes. 2025 Aug 10;11(1):159. doi: 10.1038/s41522-025-00789-5.
Laryngeal squamous cell carcinoma (LSCC) presents significant treatment challenges, especially regarding recurrence after larynx-preservation therapy. We identified distinct microbial community structures between recurrence and non-recurrence groups, particularly highlighting the genera abundance of Fusobacterium and Serratia. However, larynx-preserving therapy did not significantly alter microbial diversity in recurrent patients. Survival analysis identified Fusobacterium and Serratia as independent prognostic factors for recurrence, leading to the development of a Serratia-Fusobacterium (SF) prognostic scoring model. The SF model achieved an AUC of 81.37% for predicting recurrence, outperforming the TNM staging system. LSCC patients classified as high-risk by the SF model exhibited significantly shorter disease-free survival (DFS) compared to low-risk patients in the LSCC cohort. Furthermore, the SF model demonstrated an AUC of 78.48% in the multi-center cohort for predicting recurrence. In conclusion, the Serratia-Fusobacterium prognostic scoring model can predict LSCC recurrence after larynx-preserving therapy and provide valuable insights to inform recommendations for LSCC surveillance.
喉鳞状细胞癌（LSCC）带来了重大的治疗挑战，尤其是在喉保留治疗后的复发方面。我们在复发组和非复发组之间发现了不同的微生物群落结构，特别突出了梭杆菌属和沙雷氏菌属的丰度。然而，喉保留治疗并未显著改变复发患者的微生物多样性。生存分析确定梭杆菌属和沙雷氏菌属为复发的独立预后因素，从而开发出一种沙雷氏菌 - 梭杆菌（SF）预后评分模型。SF模型在预测复发方面的曲线下面积（AUC）为81.37%，优于TNM分期系统。在LSCC队列中，被SF模型归类为高危的LSCC患者与低危患者相比，无病生存期（DFS）显著缩短。此外，SF模型在多中心队列中预测复发的AUC为78.48%。总之，沙雷氏菌 - 梭杆菌预后评分模型可以预测喉保留治疗后LSCC的复发，并为LSCC监测建议提供有价值的见解。
